supplemental Fig. S4 ). Western blotting analyses were performed using independent biological replicate of isolated EVs, separate from those used in proteomics. F , GO analyses for biological process, cellular component, and molecular function in significant and nonsignificant regulated proteins between PC-3 and PC-3AcT EVs ( p -value <0.1). " width="100%" height="100%">
Journal: Molecular & Cellular Proteomics : MCP
Article Title: Metabolic Reprogramming Into a Glycolysis Phenotype Induced by Extracellular Vesicles Derived From Prostate Cancer Cells
doi: 10.1016/j.mcpro.2025.100944
Figure Lengend Snippet: Quantitative proteomics of PC-3 and PC-3AcT EVs. A , comparison of identified EV proteins with Vesiclepedia ( www.microvesicles.org ). Venn diagram indicated that the majority of both EV proteins were previously known EV proteins. B , most of top 100 EV proteins frequently identified in Vesiclepedia are included in our EV proteome. C , heatmap showing enrichment of EV marker proteins related to endosome, tetraspanins, membrane-binding proteins, and EV-associated proteins, which are canonical EV proteins by MISEV guidelines . D , differentially regulated proteins in PC-3 and PC-3AcT EVs are indicated in a volcano plot. Representative proteins validated by Western blotting are indicated by a green arrow. E , Western blotting showing differential expression of proteins including CTNNB1, PKM, FN1, and TSG101 as quantified in proteomics. Additionally, CTNNB1 was further validated in independently isolated EVs to confirm its differential expression observed in quantitative proteomics ( supplemental Fig. S4 ). Western blotting analyses were performed using independent biological replicate of isolated EVs, separate from those used in proteomics. F , GO analyses for biological process, cellular component, and molecular function in significant and nonsignificant regulated proteins between PC-3 and PC-3AcT EVs ( p -value <0.1).
Article Snippet: The following primary antibodies were used: rabbit anti-CD81 (dilution 1:1000, 56039S), rabbit anti-hexokinase 1 (HK1) (1:500, 2024S), rabbit anti-hexokinase 2 (HK2) (1:500, 2887), rabbit anti-phosphofructokinase (PFKP) (1:500, 8164), rabbit anti-p-ERK (1:500, 9101), rabbit anti-ERK (1:500, 9102S), rabbit anti-cyclin B1 (1:500, 12,231), rabbit anti-p-cdc42 (Thr161) (1:500, 9114S), rabbit anti-p-cdc2 (Tyr15) (1:500, 4539), mouse anti-β-actin (1:1000, 3700S) purchased from Cell Signaling Technology; mouse anti-CD9 (1:1000, MAB2529), mouse anti-fibronectin (FN1) (1:500, MAB1918) purchased from R&D Systems; mouse anti-cytochrome c (CYCS) (1:1000, 556,433) purchased from BD; rabbit anti-syntenin-1 (1:1000, ab19903), mouse anti-TSG101 (1:1000, ab125011) purchased from Abcam; mouse anti-β-catenin (CTNNB1) (1:500, sc-7963), rabbit anti-cyclin D1 (1:500, sc-718), mouse anti-pyruvate kinase M1/2 (PKM) (1:500, sc-365684) purchased from Santa Cruz Biotechnology; and OXPHOS Human WB antibody Cocktail (mouse anti-ATP5A, -UQCRC2, -SDHB, -COX2, -NDUFB8) (1:500, 45-8199) purchased from Invitrogen.
Techniques: Quantitative Proteomics, Comparison, Marker, Membrane, Binding Assay, Western Blot, Isolation